



(11) **EP 1 208 847 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 30

(51) Int Cl.:
A61K 38/13 ^(2006.01) **A61K 31/445** ^(2006.01)
A61P 37/00 ^(2006.01) **A61K 31/70** ^(2006.01)

(48) Corrigendum issued on:
14.02.2007 Bulletin 2007/07

(45) Date of publication and mention
of the grant of the patent:
27.09.2006 Bulletin 2006/39

(21) Application number: **01131018.2**

(22) Date of filing: **29.07.1997**

(54) **PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION, AS WELL AS AUTOIMMUNE OR INFLAMMATORY CONDITIONS**

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG DER
TRANSPLANTATABSTOSSUNG SOWIE DER AUTOIMMUN- ODER ENTZÜNDLICHEN ZUSTÄNDE
COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT DES ETATS DE REJET DE
GREFFE AINSI QUE DES MALADIES AUTOIMMUNES OU INFLAMMATOIRES

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**
Designated Extension States:
RO SI

(30) Priority: **30.07.1996 GB 9615942**
19.03.1997 GB 9705684

(43) Date of publication of application:
29.05.2002 Bulletin 2002/22

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
97937526.8 / 0 956 034

(73) Proprietors:
• **Novartis AG**
4056 Basel (CH)
Designated Contracting States:
**BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL
PT SE**
• **Novartis Pharma GmbH**
1230 Wien (AT)
Designated Contracting States:
AT

(72) Inventors:
• **Zenke, Gerhard**
79618 Rheinfelden (DE)
• **Schuurman, Hendrik J.**
Charlestown Navy Yard,
Charlestown MA (US)
• **Haeberlin, Barbara**
4142 Münchenstein (CH)
• **Meinzer, Armin**
79426 Buggingen (DE)

(74) Representative: **Leon, Susanna Iris et al**
Novartis AG
Corporate Intellectual Property
P.O. Box
4002 Basel (CH)

(56) References cited:
EP-A- 0 401 747 **WO-A-00/67773**
WO-A-94/09010 **WO-A-97/25977**

• **SHUURMAN H.J. ET AL: "SDZ-RAD, A NEW
RAPAMYCIN DERIVATIVE. SYNERGISM WITH
CYCLOSPORINE" TRANSPLANTATION, vol. 64,
no. 1, 15 July 1997 (1997-07-15), pages 32-35,
XP002048030**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 208 847 B8

- TU Y. ET AL: "The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice" TRANSPLANTATION, 1995, 59/2 (177-183), XP002048031 USA
- SCHULER W. ET AL: "SDZ-RAD, A NEW RAPAMYCIN DERIVATIVE. Pharmacological properties in vitro and in vivo" TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 36-42, XP002048032